Browse

KrAsG12C inhibition with Sotorasib in Advanced Solid Tumors

Cited 52 time in Web of Science Cited 65 time in Scopus
Authors
Hong, David S.; Fakih, Marwan G.; Strickler, John H.; Desai, Jayesh; Durm, Gregory A.; Shapiro, Geoffrey I.; Falchook, Gerald S.; Price, Timothy J.; Sacher, Adrian; Denlinger, Crystal S.; Bang, Yung-Jue; Dy, Grace K.; Krauss, John C.; Kuboki, Yasutoshi; Kuo, James C.; Coveler, Andrew L.; Park, Keunchil; Kim, Tae Won; Barlesi, Fabrice; Munster, Pamela N.; Ramalingam, Suresh S.; Burns, Timothy F.; Meric-Bernstam, Funda; Henary, Haby; Ngang, Jude; Ngarmchamnanrith, Gataree; Kim, June; Houk, Brett E.; Canon, Jude; Lipford, J. Russell; Friberg, Gregory; Lito, Piro; Govindan, Ramaswamy; Li, Bob T.
Issue Date
2020-09
Citation
New England Journal of Medicine, Vol.383 No.13, pp.1207-1217
Abstract
BACKGROUND No therapies for targeting KRAS mutations in cancer have been approved. The KRAS p.G12C mutation occurs in 13% of non-small-cell lung cancers (NSCLCs) and in 1 to 3% of colorectal cancers and other cancers. Sotorasib is a small molecule that selectively and irreversibly targets KRAS(G12C). METHODS We conducted a phase 1 trial of sotorasib in patients with advanced solid tumors harboring the KRAS p.G12C mutation. Patients received sotorasib orally once daily. The primary end point was safety. Key secondary end points were pharmacokinetics and objective response, as assessed according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. RESULTS A total of 129 patients (59 with NSCLC, 42 with colorectal cancer, and 28 with other tumors) were included in dose escalation and expansion cohorts. Patients had received a median of 3 (range, 0 to 11) previous lines of anticancer therapies for metastatic disease. No dose-limiting toxic effects or treatment-related deaths were observed. A total of 73 patients (56.6%) had treatment-related adverse events; 15 patients (11.6%) had grade 3 or 4 events. In the subgroup with NSCLC, 32.2% (19 patients) had a confirmed objective response (complete or partial response) and 88.1% (52 patients) had disease control (objective response or stable disease); the median progression-free survival was 6.3 months (range, 0.0+ to 14.9 [with + indicating that the value includes patient data that were censored at data cutoff]). In the subgroup with colorectal cancer, 7.1% (3 patients) had a confirmed response, and 73.8% (31 patients) had disease control; the median progression-free survival was 4.0 months (range, 0.0+ to 11.1+). Responses were also observed in patients with pancreatic, endometrial, and appendiceal cancers and melanoma. CONCLUSIONS Sotorasib showed encouraging anticancer activity in patients with heavily pretreated advanced solid tumors harboring the KRAS p.G12C mutation. Grade 3 or 4 treatment-related toxic effects occurred in 11.6% of the patients.
ISSN
0028-4793
URI
https://hdl.handle.net/10371/173208
DOI
https://doi.org/10.1056/NEJMoa1917239
Files in This Item:
There are no files associated with this item.
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse